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Abstract
Purpose: The early and accurate diagnosis of locoregional recurrence or metastasis in prostate
cancer (PC) has a significant impact on treatment options. Prostatic-specific membrane antigen
(PSMA) positron emission tomography (PET)/x-ray computed tomograph (CT) imaging has
recently been introduced as a novel procedure in managing PC. The aim of this study was to
evaluate the efficacy of [68Ga]PSMA PET/CT in managing PC patients and to compare the
detection rate of PET/CT and bone scans (BSs) in detecting bone metastasis.
Procedures: We evaluated 415 patients with PC who underwent [68Ga]PSMA PET/CT between
March 2015 and September 2018. The patients were classified into three groups: staging,
biomedical recurrence (BCR), and follow-up or monitoring, based on the intent to perform PET/CT.
Results: Weevaluated 415 patients aged 41–99 (68.25 ± 9.59). Of these patients, 344 (82.9%) had at
least one localized lesion. The detection rates were 48.3 %, 52.6 %, 74.4 %, 79.6 %, and 93.9 % for a
PSAvalue of G 0.2 ng/ml,≥ 0.2–G 0.5 ng/ml,≥ 0.5–G 1 ng/ml,≥ 1–G 2 ng/ml, and≥ 2 ng/ml, respectively
(p G 0.05). The detection rates increased significantly with higher GSs; the rates were 68.3 % (28/41),
74.5% (73/98), 93.9% (46/49), and 91% (61/67) for a GS of G 7, 7, 8, and 9 8, respectively (p G 0.05).
An ideal cut-off value of 9 1.16 ng/ml was obtained for PSA value, which equates to specificity of 75%
and sensitivity of 77 %. In comparing BSs and PET/CT, a region-based analysis showed the
superiority of PET/CT over BSs for all regions expect the skull (p G 0.05). PET/CT detected 258
suspicious regions, 255 of which were metastatic and three of which were equivocal. BSs detected
only 223 suspicious regions, 203 of which were metastatic and 20 of which were equivocal.
Conclusions: [68Ga]PSMA PET/CT showed a high detection rate for lesions in PC patients. PSA
level, GS, and a PSA doubling time of less than 6 months were shown to be the affective
variables. In addition, 68Ga-PSMA PET/CT showed better performance in detecting bone lesions
than BSs.
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Introduction
Prostate cancer (PC) is the most common malignancy and the
fifth cause of cancer-related death in men [1]. PC is classified
as localized, locally advanced (if beyond the prostate bed), or
metastatic. Patients are classified as being at low, intermediate,
or high risk of progression based on their clinical stage,
prostate-specific antigen (PSA) levels, and Gleason Score
(GS). Even with a low or undetectable PSA level, metastasis
may occur [2]. Therefore, a sensitive imaging modality capable
of diagnosing locoregional recurrence or metastasis when
treatment modalities are effective is important.
Early and accurate diagnosis is necessary to determine the
most effective patient-specific treatment plan to increase the
expected five-year survival to 100 %. Current guidelines
suggest anatomical imaging modalities, including x-ray
computed tomography (CT), magnetic resonance imaging
(MRI) , and sc in t ig raphy wi th Tc-99m-labe led
bisphosphonate—such as a methylene diphosphonate bone
scan to clarify the extent of primary or metastatic PC.
However, their sensitivity in detecting the small amounts of
PC, especially when there are low PSA values, is limited and
thus they may underestimate the extent of disease [3]. The
accurate determination of tumor sites is essential because
this helps in deciding whether surgery, systematic treatment
(such as androgen deprivation therapy (ADT) with or
without chemotherapy), or targeted therapies such as
radiotherapy are used [4].
In recent years, advances in PC-specific positron emis-
sion tomography (PET) have led to the development of new
radiotracers to evaluate the extent of disease, such as
[11C]acetate [11C]choline, [18F]fluorocyclobutane-1-carbox-
ylic acid (aka fluciclovine), and Ga-68 prostate-specific
membrane antigen ([68Ga]PSMA) [5].
Recently, prostate-specific membrane antigen (PSMA)
has received increasing attention. A transmembrane antigen,
PSMA is overexpressed in most prostatic adenocarcinomas,
and its expression levels increase with increasing tumor
dedifferentiation in hormone-refractory and metastatic PCs
[6, 7]. Radio-labeled PSMA is increasingly used in
evaluating PC. Gallium-68 labeled PSMA ([68Ga]PSMA)
PET/ CT was introduced for PC imaging a number of years
ago [8], and several recent reports have indicated its promise
in diagnosing PC, staging, follow-up, restaging in cases of
biochemical recurrence (BCR), and assessing treatment
response in patients with castration-resistant PC (mCRPC)
[9–11]. The advantages of [68Ga]PSMA imaging over
[18F]chol ine PET/CT [12] and Tc-99m-labeled
bisphosphonates [13] have been demonstrated in the
detection of PC and its metastases.
In PC, bone is the most common site for metastasis. The
majority of bone metastases in PC are osteoblastic, but other
kinds of bone metastases (such as osteolytic or mixed) can
also occur. Traditionally, the widely available and cost-
effective procedure of bone scintigraphy with Tc-99m-
labeled phosphonates has been performed to evaluate bone
metastasis for staging, follow-up, and treatment response
assessment. However, its diagnostic utility—particularly in
BCR—is limited [14]. It has also been shown that the
sensitivity of bone scans (BSs) in cases of bone marrow
involvement or early lesions with insufficient osteoblastic
activity is limited [15]. Despite these limitations, BSs have
been standard in evaluating bone metastases because of their
wide availability, whole body coverage, and low cost [16].
In this study, we evaluated the diagnostic efficacy of
[68Ga]PSMAPET/CT in a large series of PCpatients. Specifically,
we aimed to evaluate the impact of the historical data of patients,
including the GS, the PSA level and the PSA doubling time
(PSAdt) on the detection rate of PET/CT. Finally, we compared
the efficacy of PET/CT and BSs in detecting bone lesions.
Materials and Methods
Patients
In total, 415 patients who had undergone [68Ga]PSMA PET/
CT at the Nuclear Medicine Department of Razavi Hospital
in Mashhad, Iran between March 2015 and September 2018
were retrospectively studied. In addition to demographic
data, serum PSA, GS; PSAdt; and details of prior radiother-
apy, chemotherapy, or ADT were examined from the
medical records. The patients were classified into three
groups—staging, BCR, and follow-up/monitoring. The
characteristics of the patients are shown in Table 1. To
compare BSs and PC PET/CT in the detection of bone
involvement, patients with a delay of more than six months
between their BS and PC PET/CT and those who had any
changes in therapy between the two scans were excluded.
All reported evaluations were performed based on the
principles of the Helsinki Declaration and according to the
national regulations. Retrospective analysis was performed
according to ethical guidelines of the ethic commission of
our university, and the requirement for separate informed
consent for this analysis was waived.
[68Ga]PSMA-11 PET/CT Scan
[68Ga]PSMA-11 PET/CT was performed approximately 1 h
after an intravenous injection of 185 MBq (2 MBq/Kg) of
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[68Ga]PSMA on a Biograph 6 Truepoint SIEMENS PET/CT
scanner. For transmission scans, CT images were obtained
using 4 mm slice thickness on a spiral six-slice scanner. 3D
PET images were then obtained from the base of the skull to
the mid-thigh (unless there was a suspicious history of the
possibility of involvement beyond the aforementioned
boundaries) for 6–8 bed positions at 3 min per position.
The iterative method using ordered-subset expectation
maximization (OSEM) with two iterations and eight subsets,
and 5 mm Gaussian filter size was used for reconstruction of
the PET images.
Images Analysis
The [68Ga]PSMA PET/CT images were reviewed by two
nuclear medicine physicians. [68Ga]PSMA uptake was
considered physiological in the following tissues: liver,
lacrimal and salivary glands, kidneys, small intestine, spleen,
and colon. Focal tracer uptake that was higher than the
adjacent background and that was not associated with the
mentioned physiological tracer uptake was considered as
indicative of PC. PET-positive lesions were classified as
local metastases (prostate/prostate bed metastases, and/or
pararectal lymph nodes (LNs) and/or iliac LNs) or distant
metastases (LNs above the iliac bifurcation and/or retroper-
itoneal LNs and/or bone lesions and/or other visceral
lesions).
Bone Scan Analysis
The skeletal system was classified into eight regions—skull,
sternum, ribs, vertebrae, clavicle, pelvis, scapulae, and upper
and lower limbs. BSs and [68Ga]PSMA PET/CT images
were reviewed by two nuclear medicine physicians. A three-
point visual scale—negative (normal or benign), equivocal,
and positive—was determined to classify bone metastasis at
each region.
The final diagnosis was according to the blending of
correlative imaging, histopathologic examinations, and also
clinical follow-up.
Table 1 Characteristics of patients
Characteristic All patients PSMA-positive PSMA-negative
Study N = 415 N = 344 N = 71
Staging 45 (10.8) 40 (11.6) 5 (7)
Recurrence 194 (46.7) 153 (44.5) 41 (57.7)
Follow-up/monitoring 176 (42.4) 151 (43.9) 25 (35.2)
Age (years) N = 396 N = 330 N = 66
Mean ± SD 68.25 ± 9.59 68.48 ± 9.58 67.11 ± 9.63
Range 41–99 41–99 48–92
PSA (ng/ml) N = 374 N = 308 N = 66
Mean ± SD 67.96 ± 461.15 82.04 ± 507.197 2.22 ± 5.27
Range 0.002–5000 0.03–5000 0.002–33
PSA value (ng/ml), n (%) N = 374 N = 308 N = 66
G 0.2 29 (7) 14 (4.5) 15 (21.4)
≥ 0.2 to G 0.5 38 (9.2) 20 (6.5) 18 (25.7)
≥ 0.5 to G 1 39 (9.4) 29 (9.4) 10 (14.3)
≥ 1 to G 2 54 (13) 43 (14) 11 (15.7)
≥ 2 214 (51.6) 202 (65.6) 12 (17.1)
PSA doubling time (months), n (%) N = 140 N = 113 N = 28
G 6 months 87 (62.1) 76 (67.2) 12 (43)
≥ 6 months 53 (37.9) 37 (32.8) 16 (57)
Radical prostatectomy, n (%) N = 415 N = 345 N = 70
Yes 255 (61.4) 203 (58.8) 52 (74.3)
No 160 (38.6) 142 (41.2) 18 (25.7)
Hormone therapy N = 412 N = 342 N = 70
Yes 216 (52.5) 190 (55.6) 26 (37.1)
No 196 (47.5) 152 (44.4) 44 (62.9)
Chemotherapy/radiotherapy N = 415 N = 345 N = 70
Radiotherapy 128 (30.8) 109 (31.6) 19 (27.1)
Chemotherapy 10 (2.4) 9 (2.6) 1 (1.4)
Both 29 (7) 28 (8.1) 1 (1.4)
None 248 (59.8) 199 (57.7) 49 (70)
Gleason Score N = 255 N = 208 N = 47
Mean ± SD 7.6 ± 1.13 7.73 ± 1.12 7.06 ± 0.98
G 7 41 (16) 28 (13.5) 13 (27.7)
7 98 (38.5) 73 (35.1) 25 (53.2)
8 49 (19.2) 46 (22.1) 3 (6.4)
≥ 9 67 (26.3) 61 (29.3) 6 (12.8)
N, the number of patients
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Statistical Analysis
PSA values were classified as G 0.2 ng/ml, 0.2–G 0.5 ng/ml,
0.5–G 1 ng/ml, 1–G 2 ng/ml, and ≥ 2 ng/ml; GSs were
classified as G 7, 7, 8, and 9 8; and PSAdt was classified as
G 6 months and ≥ 6 months. The detection rate of
[68Ga]PSMA PET/CT and BSs was defined as the ratio
between the numbers of cases with a positive scan to the
whole number of patients. Continuous variables were
presented as mean ± SD, and categorical variables were
presented as number and percentages. Wilcoxon rank and
chi-squares tests were used to compare continuous and
categorical variables, respectively. A multivariable logistic
model was used to evaluate the relationship between the
results of [68Ga]PSMA PET/CT and BSs and demographic
and clinical features. Receiver operating characteristic
(ROC) curve analysis was used to determine the cut-off
value, area under the curve (AUC), and 95 % confidence
interval (CI). A p value G 0.05 was considered statistically
significant. Data analysis was performed using SPSS
(Windows software version 20, SPSS Inc.).
Results
Patients
We evaluated 415 patients with PC who had undergone
[68Ga]PSMA PET/CT. They ranged in age from 41–99, with
a mean age of 68.25 ± 9.59. No adverse or detectable
pharmacological effects were observed in patients following
the injection of a radiotracer. PSA values were 0.002–5000
ng/ml with a mean of 67.96 ± 461.155 ng/ml. GSs ranged
from 6–10 with a mean of 7.6 ± 1.13. Of the 415 patients
evaluated, 255 (61.4 %) had radical prostatectomy, 216 had
hormone therapy (ADT), 128 had radiotherapy, 10 had
chemotherapy, and 29 had both chemotherapy and radio-
therapy. Of the 415 patients, 45 (10.8 %) presented for
staging, 194 (46.7 %) presented for recurrence, and 176
(42.5 %) presented for follow-up/monitoring; there were no
statistical differences between mean PSA values and GSs in
these groups (p 9 0.05). The patient characteristics are
shown in Table 1.
Detection Efficacy of [68Ga]PSMA
Of the 415 patients, 344 (82.9 %) were shown to have at
least one localized region classified as suspicious for PC.
There were no significant statistical differences among the
three groups. The detection efficacy of PET/CT was 89 %
(40/45), 79 % (153/194), and 86 % (151/176) for the
staging, BCR, and follow-up groups, respectively (p 9 0.05).
We found a direct relationship between PSA values and
the detection rate (p G 0.05) (Fig. 1). The detection efficacy
of [68Ga]PSMA PET/CT was 48.3 % (14/29) for a PSA
value G 0.2 ng/ml; 52.6 % (20/38) for a PSA value ≥ 0.2–G
0.5 ng/ml; 74.4 % (29/39) for a PSA value ≥ 0.5–G 1 ng/ml;
79.6 % (43/54) for a PSA value ≥ 1–G 2 ng/ml; and 93.9 %
for a PSA value ≥ 2 ng/ml (p G 0.05). In patients with a
positive [68Ga]PSMA PET/CT, the PSA values were
significantly higher than in patients with a negative PET/
CT (82.30 ± 508 ng/ml vs. 2.24 ± 5.23 ng/ml, p = 0.03).
The detection efficacy of [68Ga]PSMA PET/CT was 68.3 %
(28/41), 74.5 % (73/98), 93.9 % (46/49), and 91 % (61/67) for a
GS of G 7, 7, 8, and 9 8 respectively, indicating a significant
association between a positive [68Ga]PSMA PET/CT and the
GS (p G 0.05) (Fig. 2). In addition, the mean GS was
significantly higher for patients with a positive [68Ga]PSMA
PET/CT than for patients with a negative [68Ga]PSMA PET/CT
(7.73 ± 1.12 vs. 7.06 ± 0.98, p = 0.001).
There was a trend towards a higher detection rate in
patients with radiotherapy/chemotherapy (87 % vs. 79.8
%) (p G 0.05). The detection rate of PET/CT was lower for
patients with a history of RP (88.1 % vs. 79.6 %, p G
0.05). The detection rate of PET/CT was significantly
higher for patients with a PSAdt of less than 6 months than
for patients with a PSAdt of more than 6 months (86.4 %
vs. 69.8 %, p G 0.05).
The PSA value was relatively lower in patients with a
prior history of ADT (48.9 ± 363.98 vs. 61.37 ± 407.18
ng/ml) (p = 0.51) and was significantly lower in patients
with a prior history of RP (46.37 ± 348.91 vs. 107.99 ±
617.30, p = 0.047). There was a significant direct relation-
Fig. 1. Detection rate (%) of [68Ga]PSMA in relation to PSA
values (ng/ml).
Fig. 2. [68Ga]PSMA detection rate (%) in relation to Gleason
score (GS).
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ship between the number of lesions and PSA value (2.52 ±
3.73 for a PSA value G 0.2 ng/ml; 1.68 ± 3.00 for a PSA
value ≥ 0.2–G 0.5 ng/ml; 2.28 ± 3.5 for a PSA value ≥ 0.5–G
1 ng/ml; 2.09 ± 2.81 for a PSA value ≥ 1–G 2 ng/ml; and
5.73 ± 4.59 for a PSA value ≥ 2 ng/ml, p G 0.0001) and GS
(3.27 ± 4.50, 2.59 ± 3.57, 5.31 ± 4.57, 5.33 ± 4.64 for a GS
of G 7, 7, 8, and 9 8, respectively, p G 0.0001). The mean
number of lesions in patients with a PSAdt of less than 6
months was significantly higher than that of patients with a
PSAdt of more than 6 months (5.8 ± 4.74 vs. 2.21 ± 3.35, p
G 0.0001) (Fig. 3). In addition, the mean number of lesions
in patients with a prior history of RP was significantly lower
than that in patients without such a history (4.93 ± 3.81 vs.
3.81 ± 4.33, p = 0.022).
In the evaluation of lesion detection results, 71 patients
(17.1 %) had a normal [68Ga]PSMA PET/CT scan, 100
(24.1 %) showed only local uptake (prostate/prostate bed),
and 244 (58.8) showed at least one extraprostatic lesion. In
230 (55 %) patients, at least one distant lesion was seen.
Table 2 describes the lesion detection results. The number
and location of lesions is given in Tables 3 and 4.
ROC Analysis
We analyzed the PSA value data to determine the cut-off
value using the receiver operating characteristic (ROC)
curve. An ideal cut-off value of 9 1.16 was obtained using
ROC analyses (AUC = 0.805; 95 % CI 0.749–0.861; p G
0.0001). The application of this cut-off is related to a
specificity of 75 % and a sensitivity of 77 % (Fig. 4).
Comparison of [68Ga]PSMA PET/CT and BS
Of the 415 patients, 227 underwent a BS to determine bone
involvement before PET/CT. PET/CT detected 258 suspi-
cious regions, 255 of which were metastatic and 3 of which
were equivocal (Table 3). BSs detected 223 suspicious
regions, 203 of which were metastatic and 20 of which were
equivocal. As seen in Table 3, PET/CT showed significantly
better performance in detecting lesions in all regions except
the skull and vertebrae compared with BSs (p G 0.05). BSs
showed significantly more lesions in the skull than PET/CT
(p G 0.05). The two types of scans showed relatively
equivocal results for the vertebrae, although BSs detected
11 equivocal lesions.
Discussion
In the last years, several studies evaluated the valuable role
of [68Ga]PSMA PET-CT on management of PC patients
around the world; however, there are only a few studies with
limited number of patients on this topic in middle east
population, thus we decided to perform this study with
acceptable number of evaluated patients.
In PC patients, the early, localized and accurate detection
of cancer-related involvement can impact and lead to
changes in treatment decisions as local cancer is usually
treated locally and metastatic cancer requires additional
Fig. 3. Detection rate (%) of [68Ga]PSMA in relation to
PSAdt and radical prostatectomy.
Table 2 Location of detected sites in [68Ga]PSMA PET/CT
Site Number (%) of patients
with suspicious site
Pelvic LNs 71 (17.1)
Local 19 (4.6)
Pelvic LNs + distant LNs 101 (24.3)
Local + pelvic LNs 19 (4.6)
Pelvic LNs + bone 14 (3.4)
Distant LNs 11 (2.7)
Bone 42 (10.1)
Local + bone 42 (10.1)
Distant LNs + bone 20 (4.8)
Local + pelvic LNs + distant LNs 7 (1.7)
Pelvic LNs + distant LNs + bone 12 (2.9)
Lung ± liver 3 (0.7)
Local + distant LNs 5 (1.2)
Local + pelvic LNs + distant LNs + bone 11 (2.7)
Local + pelvic LNs + bone 12 (2.9)
Bone + local + distant LNs 11 (2.7)
Normal 71 (17.1)
LN, lymph node
Table 3 The number and location of detected legions in [68Ga]PSMA PET/
CT and bone scan (BS)
PET/CT number of lesions BS number of lesions
Positive Equivocal Positive Equivocal
Skull 10 0 14 0
Vertebrae 68 0 67 11
Ribs 50 0 35 1
Sternum 10 0 6 0
Clavicle 7 0 5 1
Pelvic 74 3 57 4
Upper limbs-scapula 18 0 6 3
Lower limbs 18 0 13 0
Total 255 3 203 20
Analysis was done in all cases whom had either 68Ga-PSMA PET/CT or
bone scan
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systematic therapy such as chemotherapy or radionuclide
therapy. Traditionally, The European Association of Urology
guidelines for the detection and evaluation of any local or
metastatic disease have suggested the use of CT, MRI, and BSs
(if PSA levels are 9 10 ng/ml) [2]. However, these modalities
have low specificity and give limited information about soft
tissue metastasis [17]. For example, although MRI plays an
increasing role in management of PC patients, in several
studies, the superiority of 68Ga-PSMA PET-CT in PC patients
has been proved [18–20]. Sawicki et al. [18] compared
detection rate of whole body MRI and [68Ga]PSMA PET-CT
on BCR patients after prostatectomy. They reported that
[68Ga]PSMA PET-CT significantly out-performed whole body
MRI in the detection of BCR in PC patients.
In patients with PSA values less than 7 ng/ml, BSs are
reported to have low efficacy and CT has shown low
sensitivity in detecting local and LN involvement [21].
Because the conventional imaging procedures, including
MRI, CT, BSs, and other forms of PET have low sensitivity
for the early detection of involved regions [11, 22], the aim
of this study was to assess the detection efficacy of
[68Ga]PSMA PET/CT in PC patients and to compare that
with the efficacy of traditional BSs in detecting bone
involvement. Several studies have shown [68Ga]PSMA to
have high diagnostic efficacy [5, 9, 12, 13, 22].
The early detection of PC-related involvement is both very
important and effective in determining the best treatment plan.
In our study, we evaluated [68Ga]PSMA PET/CT in 415 PC
patients, and overall [68Ga]PSMA PET/CT showed a high
detection rate of 82.9 % (344/415), 88.9 % (40/45), 78.9 %
(153/194), and 85.8 % (151/176) in staging, BCR, and follow-
up patients, respectively. Our results correlate with those of
previous studies in terms of the overall detection efficacy of
[68Ga]PSMA PET/CT [5, 19]. The efficacy in our study ranged
from 82.2–90.7 %, thus proving the capability of this modality
to detect PC-related involvement. Hamed et al. [5] reported an
overall detection rate of 87.8 %, which was relatively higher
than the current study. However, in the largest study that
included 1007 patients, Afshar-Oromieh et al. [22] obtained a
detection rate of 79.5 %, which was relatively lower than our
study. There was no significant difference in detection rate
within three groups; therefore, it could be concluded that 68Ga-
PSMA PET-CT is helpful for management of all PC patients.
According to our results, the detection rate of [68Ga]PSMA
PET/CT increased with increasing PSA values; it was 48.3 %
(14/29) for a PSA value G 0.2 ng/ml; 52.6 % (20/38) for a PSA
value ≥ 0.2–G 0.5 ng/ml; 74.4 % (29/39) for a PSA value ≥
0.5–G 1 ng/ml; 79.6 % (43/54) for a PSA value ≥ 1–G 2 ng/ml;
and 93.9 % for a PSA value ≥ 2 ng/ml. These findings correlate
with those of previous studies [5, 11]. Our study revealed a
direct relationship between GS and the detection efficacy of
PET/CT. The detection efficacy of PET/CT was 68.3 % (28/
41), 74.5 % (73/98), 93.9 % (46/49), and 91 % (61/67) for GSs
of G 7, 7, 8, and 9 8, respectively. This is in agreement with
Eiber et al. [10], who reported a significant direct
relationship between higher GSs and a positive
[68Ga]PSMA PET/CT. However, this contrasts with the
results of Hamed et al. [5] and Afshar-Oromieh et al.
[22], who found no significant relationship between GSs
and a positive [68Ga]PSMA PET/CT. Overall, it can be
concluded that increases in PSA value and GSs indicate
the progression of the disease. Therefore, due to the high
detection rate of [68Ga]PSMA PET/CT, even with low
GSs and PSA values, it can be used as a standard
modality to evaluate PC patients.
In our study, the detection rate was significantly higher in
patients with a PSAdt of less than 6 months than in patients
with a PSAdt of more than 6 months. Our results correlate
with those of Ceci et al. [23], who reported positive PSMA
PET in 93 % of patients with a PSAdt of G 6.5 months
compared with 34.8 % in patients with a PSAdt of 9 6.5
months. However, other studies have found no significant
relationship between PSAdt and pathological [68Ga]PSMA
PET/CT [9, 10, 22].
Table 4 Classification of the patients based on number of detected lesions
on [68Ga]PSMA PET/CT
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Fig. 4. ROC curve for PSA value (cut-off value of 9 1.16
ng/ml, AUC = 0.805; 95 % CI 0.749–0.861; p G 0.0001).
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Our results indicate that 100 patients (24.1 %) showed
only local uptake (prostate/prostate bed) and 244 (58.8)
showed at least one extraprostatic lesion, which correlates
with the findings of Einspieler et al. [24] (59.8 %) and is
almost in line with the results of Hamed et al. [5] (69.1 %).
Therefore, because [68Ga]PSMA can detect extraprostatic
metastases early and because the management of patients
strongly depends on the site and extent of involvement, it
could be a valuable and important modality in managing PC
patients in helping to determine appropriate therapy and in
avoiding futile treatment [5].
In our study, an ideal cut-off value of 9 1.16 ng/ml for
PSA value was obtained to detect PC-related involvement
which is higher than the 0.67 ng/ml obtained by Sanli et al.
[25]. In our study, 20 % (9/45) of staging patients had no or
minimal uptake in the prostate gland, despite proven PC.
This is relatively equivocal equivalent to the results of a
previous study [26]. This result might be due to the
neuroendocrine differentiation of PC, which may be the
main cause of false negatives in PC diagnosis and which
limits the detection efficacy of [68Ga]PSMA [27].
In comparing [68Ga]PSMA PET/CT and BSs, the
superiority of PET/CT in all regions except the skull and
vertebrae was revealed. Our results correlate with those of
Pyka et al. [28], who concluded [68Ga]PSMA PET is better
than BSs in detecting bone lesions in PC patients. Therefore,
it can be concluded that if [68Ga]PSMA has been obtained,
generally a BS is not needed and it can become a “one-stop-
shop” in PC evaluation. In addition, the number of equivocal
lesions appearing on BSs was significantly higher compared
with [68Ga]PSMA PET/CT, which can result in limiting
additional studies to clarify unclear BS findings. A lower
number of detected lesions in the skull in [68Ga]PSMA PET/
CT compared with BSs relates to the area covered by PET,
which does not routinely include the cranium.
It should be mentioned that, although PSA cut-off is a
worthwhile item of PSMA PET/CT indication, patients with
low PSA values should be imaged with PSMA PET/CT
because at that stage of disease changes in management are
more drastic.
The main drawbacks of this study include its retrospec-
tive design, single-center site, and the inability to generalize
our values. In our study, the time interval between scans and
therapy was not considered. In addition, our patients had
different types of therapy (including focal and systematic)
and wide variation in PSA values. It must also be mentioned
that the classification of some cases into the staging,
recurrence, and follow-up/monitoring groups was challeng-
ing. Cost-effectiveness analysis was not conducted. How-
ever, although [68Ga]PSMA PET/CT is relatively expensive
compared with other imaging modalities, it can detect any
prostate-related involvement and therefore can have a
positive impact on patient management and can guide
clinicians in making appropriate treatment plans, thus
reducing patient costs.
Conclusion
This study demonstrates the promising detection rate of
[68Ga]PSMA PET/CT for PC patients, even those with low
PSA values. It also shows the superiority of [68Ga]PSMA
PET/CT in detecting bone involvement compared with BSs.
Because PSMA is heavily expressed in PC, even in the early
stages, it can be used as a standard tool in PC work ups.
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